Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann S de BonoJoaquin MateoKarim FizaziFred SaadNeal ShoreShahneen SandhuKim N ChiA Oliver SartorNeeraj AgarwalDavid OlmosAntoine Thiery-VuilleminPrzemyslaw TwardowskiNiven MehraCarsten GoesslJinyu KangJoseph BurgentsWenting WuAlexander KohlmannCarrie A AdelmanMaha HussainPublished in: The New England journal of medicine (2020)
In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone. (Funded by AstraZeneca and Merck Sharp & Dohme; PROfound ClinicalTrials.gov number, NCT02987543.).